Coeur d'Alene High School has announced its fall 2024 honor roll.
Ridgeline High School has announced its first-semester honor roll for the 2024-25 school year. Eligible students are listed first by grade and GPA, then alphabetically by last name. 12th grade 4.0 ...
Kirsty Coventry is a lesson in how to have it all — and strive for more. Decades younger than her rivals, she’s now in the ...
Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...
Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.
Eli Lilly plans four new U.S. manufacturing sites, expanding domestic production and reshoring pharmaceutical ingredient manufacturing. $50B expansion since 2020 includes four sites, creating over ...
Covering everything from politics to sport, business to entertainment as well as news from around the country and around the world, Rod Emmerson takes pen to paper to give us his take on the day ...
Eli Lilly (LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce ...
For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the newly introduced Zepbound Self Pay Journey Program. The company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results